SG Americas Securities LLC Has $938,000 Position in Horizon Pharma PLC (HZNP)

SG Americas Securities LLC reduced its holdings in Horizon Pharma PLC (NASDAQ:HZNP) by 51.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 64,237 shares of the biopharmaceutical company’s stock after selling 67,245 shares during the period. SG Americas Securities LLC’s holdings in Horizon Pharma were worth $938,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its holdings in Horizon Pharma by 1.1% in the second quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock valued at $1,495,000 after buying an additional 1,379 shares during the period. Fox Run Management L.L.C. raised its holdings in Horizon Pharma by 21.5% in the fourth quarter. Fox Run Management L.L.C. now owns 19,200 shares of the biopharmaceutical company’s stock worth $280,000 after purchasing an additional 3,400 shares during the period. Advantage Investment Management LLC raised its holdings in Horizon Pharma by 164.8% in the third quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 4,900 shares during the period. Nationwide Fund Advisors raised its holdings in Horizon Pharma by 6.6% in the second quarter. Nationwide Fund Advisors now owns 101,186 shares of the biopharmaceutical company’s stock worth $1,201,000 after purchasing an additional 6,255 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in Horizon Pharma by 3.0% in the third quarter. New York State Common Retirement Fund now owns 238,613 shares of the biopharmaceutical company’s stock worth $3,026,000 after purchasing an additional 7,000 shares during the period. Institutional investors and hedge funds own 85.70% of the company’s stock.

Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at $14.09 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.52 and a debt-to-equity ratio of 1.89. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $17.69. The stock has a market cap of $2,310.00, a price-to-earnings ratio of -4.63, a PEG ratio of 0.65 and a beta of 1.35.

HZNP has been the topic of several analyst reports. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a report on Wednesday, December 27th. BidaskClub upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. UBS Group set a $20.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a report on Thursday, November 30th. Jefferies Group increased their target price on shares of Horizon Pharma from $16.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, November 7th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 target price on shares of Horizon Pharma in a report on Sunday, October 22nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. Horizon Pharma has a consensus rating of “Buy” and an average price target of $19.25.

ILLEGAL ACTIVITY NOTICE: This story was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://ledgergazette.com/2018/02/16/sg-americas-securities-llc-has-938000-position-in-horizon-pharma-plc-hznp.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply